Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, anticipates strong growth in membership in 2025. The momentum is expected to build upon the record-setting performance already achieved this year in terms of network and membership expansion.
“According to a company news release, membership is expected to grow by 70% or 7,000 members, a major increase from the numbers reported this year. Astiva Health started off with a membership jump in January 2024, when it reached 10,000 members (22% higher than the 3,100 members recorded in January 2023), and then again in June 2024 when 13,000 members were recorded,” reads a recent article discussing the company. “This membership increase of more than four times reflects the growing demand for Astiva Health’s unique services and approach to healthcare… In addition to the remarkable increase in membership, the company successfully established a strong network of over 12,940 providers, including 10,355 specialists and 2,585 primary care physicians, enabling it to offer comprehensive care to its rapidly growing member base.”
To view the full article, visit https://ibn.fm/iq8VJ
About Astiva Health
Astiva Health is a fast-growing MAPD health plan committed to redefining personalized and comprehensive healthcare standards. With a mission to elevate individuals’ well-being, Astiva Health specializes in innovative health plans tailored to meet its members’ unique needs. The organization prioritizes a culturally responsive approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Astiva Health’s dedication to serving the underserved population fulfills a critical societal need and positions the company to tap into a market segment with significant growth potential. For more information about Astiva Health and its services, please visit www.AstivaHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to Astiva are available in the company’s newsroom at https://ibn.fm/Astiva
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
